PITTSBURGH & LONDON--(BUSINESS WIRE)--Helomics™ Corporation, a privately-held personalized healthcare company that provides comprehensive tumor profiling products and services based on both live and fixed cell assays, announced today a groundbreaking partnership with Genomics England as part of the inaugural group of industry collaborators to join the 100,000 Genomes Project. Helomics will serve as a founding member and the sole diagnostics-focused company represented in the Genomics Expert Network for Enterprises (GENE) Consortium, which is also comprised of leading global pharmaceutical and biotech companies including AbbVie, AstraZeneca, Alexion Pharmaceuticals, Biogen, Dimension Therapeutics, GlaxoSmithKline, Roche, Takeda Pharmaceuticals and UCB.
Through this unique partnership Helomics will collaborate with clinicians, researchers and the pharmaceutical and biotech companies within the GENE Consortium on a year-long industry trial to discover new insights and approaches that could ultimately improve patient outcomes. As the only diagnostics-focused company in the GENE Consortium, Helomics will provide its unique expertise and PCAPTM tumor profiling technology to identify new biomarkers that could be used to develop more advanced cancer diagnostic tests and ultimately lead to new levels of personalized medicine.
Genomics England, a company wholly owned and funded by the U.K. Department of Health, was set up by U.K. Prime Minister David Cameron in 2012, with a package of investment worth more than £300 million. The project is pioneering new research to decode 100,000 human genomes and translate that work into the National Health Services (NHS) by 2017. The project’s four main aims are: to create an ethical and transparent program based on consent; to bring benefit to patients and set up a genomic medicine service for the NHS; to enable new scientific discovery and medical insights; and to kick start the development of a UK genomics industry. The project focuses on patients with rare diseases and six common cancers.
“It is an honor and an exciting opportunity to contribute our cancer diagnostics expertise to this impressive group of international industry leaders,” said Neil Campbell, President and CEO of Helomics. “We are exceedingly proud to join the 100,000 Genomes Project as part of the GENE Consortium, which we believe will help unlock new insights into the genetic impact on major diseases, as well as inform and accelerate the development of new diagnostics and therapies designed to improve outcomes for patients throughout the world.”
About Helomics Corporation, Inc.
Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.
This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.